July 8, 2021

BONESUPPORT HOLDING AB (publ) – Interim Report Q2 2021 Invitation to conference call and webcast

Lund, Sverige, 10.00 CET, 8 July 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Re...
Read more
July 8, 2021

Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical hold

STOCKHOLM — July 8, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematologic...
Read more
July 7, 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

• Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record Copenhagen, Denmark, 7 July 2021 – Adcendo, a biotech company devel...
Read more
July 1, 2021

Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer

Oslo, Norway, 1 July 2021 – Targovax ASA (OSE: TRVX) announces the appointment of Dr Lone Ottesen, MD, PhD as Chief Development Officer (CDO). She will take a lea...
Read more
July 1, 2021

Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer

Oslo, Norway, 1 July 2021 Nordic Nanovector ASA (OSE: NANOV) announces that Ms. Malene Brondberg has been appointed interim Chief Executive Officer with immediate effect. Ms...
Read more
June 24, 2021

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

Dr. Ways’ Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce’s Goal to Expand Portfolio of Indications for...
Read more
June 23, 2021

InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation

Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Dat...
Read more
June 22, 2021

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Oslo, Norway, 22 June 2021 Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotom...
Read more
June 22, 2021

Targovax receives Fast Track designation for ONCOS-102 in melanoma

The US FDA grants ONCOS-102 Fast Track designation for PD-1-refractory advanced melanomaFast Track designation further strengthens the opportunity for accelerated approval for ONC...
Read more
June 21, 2021

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalizati...
Read more